BGLC BioNexus Gene Lab Corp.
USHealthcareAs of 2026-07-09 16:00
Why BGLC matters now
BioNexus Gene Lab Corp. (BGLC) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.73 with -10.36% on the session and $3.5M in market capitalization; recent performance reads 1-month +24.29% and YTD -33.92%.
The latest financial table shown here is Q1 2026, with revenue of $22.8K, net income of $-543.6K, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.6%.
The latest indexable market news headline is "BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development" from GlobeNewsWire.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.78
P/S
0.99
EV/EBITDA
-0.55
DCF Value
$-13.16
FCF Yield
-22.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
13.5%
Operating Margin
-54.9%
Net Margin
-54.7%
ROE
-37.4%
ROA
-13.7%
ROIC
-14.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.8K | $-543.6K | $-0.22 |
| Q4 2025 | $483.8K | $-1.0M | $-0.53 |
| FY 2025 | $7.4M | $-3.0M | $-1.61 |
| Q3 2025 | $2.5M | $-709.0K | $-0.39 |
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
MY
Exchange
—
Beta
2.19
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.